Cosciens Biopharma Inc Share Price

NASDAQ: CSCI

$2.73

-0.35

(-11.36%)

as on September 4, 2025 at 1:29 am IST

$₹

The stock has been delisted from the stock exchange on 29 Aug 2025

Cosciens Biopharma Inc Stock Performance

as on September 4, 2025 at 1:29 am IST

Day's Low
Day's High
$2.5
Day's Price Range
$2.98
$2.73
8.42%
Downside
9.16%
Upside
52 Week's Low
52 Week's High
$1.96
52-Week Price Range
$4.61
$2.73
28.21%
Downside
68.70%
Upside

Cosciens Biopharma Inc share price movements today

Previous Close: $3.08
Open: $2.91
Volume: 298.2K
Day's Low - High: $2.5 - $2.98
52 Week Low - High: $1.96 - $4.61

Cosciens Biopharma Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Cosciens Biopharma Inc Stock Fundamentals & Key Indicators

Check Cosciens Biopharma Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

0.00%

Cosciens Biopharma Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cosciens Biopharma Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Cosciens Biopharma Inc	NA	$-	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Cosciens Biopharma Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	1	1	1	1	1	2	1	3	1	2
Gross Profit	0	0	0	0	0	0	0	2	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	0	0	0	-1	-1	-1	-5	-6	-3	-2
Net Profit Margin	-11.02%	-61.78%	-39.75%	-118.94%	-68.14%	-60.85%	-307.59%	-202.62%	-243.67%	-98.25%

Cosciens Biopharma Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	7	10	10	8	9	9	10	10	5	13
Gross Profit	5	6	5	4	4	4	6	6	2	6
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	3	2	0	0	0	1	2	2	-2	-15
Net Profit Margin	46.14%	26.47%	-7.41%	-2.72%	-8.79%	12.27%	19.57%	23.66%	-48.79%	-111.07%

Insights on Cosciens Biopharma Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.49M → 2.74M (in $), with an average increase of 45.6% per quarter
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -6.73M → -2.70M (in $), with an average increase of 59.8% per quarter
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 76.9% return, outperforming this stock by 102.1%
NEGATIVE IMPACT
Price Dip
In the last 1 month, CSCI stock has moved down by -22.3%

About Cosciens Biopharma Inc

COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Organisation	Cosciens Biopharma Inc
E-voting on shares	Click here to vote

FAQs

What is Cosciens Biopharma Inc share price today?

Cosciens Biopharma Inc share price today is $2.73 as on September 4, 2025 at 1:29 am IST at the close of the market. Cosciens Biopharma Inc share today touched a day high of $2.98 and a low of $2.5.

What is the 52 week high and 52 week low for Cosciens Biopharma Inc share?

Cosciens Biopharma Inc share touched a 52 week high of $4.61 on March 19, 2025 and a 52 week low of $1.96 on March 13, 2025. Cosciens Biopharma Inc stock price today i.e. September 4, 2025 at 1:29 am IST is closed at $2.73,which is 40.72% down from its 52 week high and 39.29% up from its 52 week low.

How to invest in Cosciens Biopharma Inc Stock (CSCI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cosciens Biopharma Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cosciens Biopharma Inc Shares that will get you 0.5495 shares as per Cosciens Biopharma Inc share price of $2.73 per share as on September 4, 2025 at 1:29 am IST.

What is the minimum amount required to buy Cosciens Biopharma Inc Stock (CSCI) from India?

Indian investors can start investing in Cosciens Biopharma Inc (CSCI) shares with as little as ₹88.141 or $1 (as of September 16, 2025 at 2:11 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Cosciens Biopharma Inc stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 2:11 am IST). Based on Cosciens Biopharma Inc share’s latest price of $2.73 as on September 4, 2025 at 1:29 am IST, you will get 3.6630 shares of Cosciens Biopharma Inc. Learn more about fractional shares .